Sign in
Taking people in United StatesPhase 3

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

Key facts

Who runs it
Ipsen
Where
Ann Arbor, Asheville, Atlanta, Aurora, Baltimore, Beavercreek, Bellevue, Boston, Chandler, Chapel Hill, Charleston, Charlotte, Charlottesville, Chicago, Cleveland, Colorado Springs, Cordova, Coronado, Dallas, Detroit, Durham, Englewood, Hershey, Houston, Indianapolis, Iowa City, Johnson City, La Jolla, Littleton, Los Angeles, Louisville, Madison, Miami, Murray, New Albany, New Haven, New York, Newburgh, Omaha, Pasadena, Philadelphia, Phoenix, Providence, Rapid City, Redwood City, Richmond, Rochester, Sacramento, San Antonio, San Francisco, Seattle, St Louis, and Washington D.C., United StatesSee the 69 sitesAlso in 24 other countries, 162 sites
Status
Recruiting
Phase
Phase 3
People taking part
350 people, planned
Started
14 May 2026
Expected to end
31 May 2031
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Elafibranor
  • Placebo
Record updated
23 October 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Adults participants aged 18 years or older
  • Confirmed diagnosis of primary sclerosing cholangitis based on standard clinical, biochemical, and imaging criteria
  • Compensated liver disease at screening
  • Stable background therapy, where applicable prior to study entry
  • Women of childbearing potential have to apply during the entire duration of the study a highly effective method of birth control
  • Ability to provide written informed consent and comply with study procedures

Who cannot take part

  • History or presence of other concomitant chronic liver disease
  • History of biliary intervention within 60 days prior to the screening period, and/or presence of percutaneous drain or bile duct stent at SV
  • History of bacterial cholangitis, and/or participant on antibiotics for prophylaxis of recurrent cholangitis within 60 days prior to the SV
  • Administration of the following medications are prohibited as specified below:; 3 months prior to baseline: norucholic acid, fibrates, seladelpar and glitazones
  • Participants who are currently participating in, plan to participate in, or have participated in an investigational drug or medical device study containing active substance within 30 days or five half-lives, whichever is longer, prior to the SV. - Participants with previous exposure to elafibranor
  • History of alcohol abuse, or other substance abuse within 1 year prior to SV
  • History of hepatic decompensation, including: i) History of liver transplantation, current MELD 3.0 score ≥12 due to hepatic impairment
  • Known malignancy or history of malignancy within the last 5 years, with the exception of local, successfully treated basal cell carcinoma or in-situ carcinoma of the uterine cervix
  • Medical conditions that may cause non-hepatic increases in ALP (e.g. Paget's disease)
  • Significant renal disease,
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that contraindicates participation in the study
  • Participant has or is known to have tested positive for human immunodeficiency virus (HIV) type 1 or 2 at SV
  • 3 months prior to baseline: cyclosporine, mycophenolate, pentoxifylline, and chronic systemic corticosteroids (except as part of management of IBD at an ongoing stable dose); potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid, isoniazid, or nitrofurantoin)
  • Electrocardiogram (ECG) with QT interval corrected by Fridericia's formula (QTcF) >450 msec in males or QTcF >470 msec in females for participants without bundle branch block
  • For female participants: known pregnancy, or has a positive serum pregnancy test, or lactating
  • Medical conditions that may diminish life expectancy to <2 years
  • Evidence of complications of cirrhosis
  • Participants with cirrhosis who are also classified as Child-Pugh B or C based on the Child Pugh score
  • History or any current suspicion of cholangiocarcinoma or hepatocellular carcinoma
  • Regular alcohol intake in excess of the recommended limit of 2 standard drinks per day for men or 1 standard drink per day for women
  • Mental instability or incompetence

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

Also in 24 other countries, 162 sites

  • University of MichiganAnn Arbor, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Digestive Health Partners, PAAsheville, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Piedmont Hospital - Piedmont Transplant InstituteAtlanta, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • University of Colorado Hospital - Anschutz Outpatient PavilionAurora, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Johns Hopkins University School Of MedicineBaltimore, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Mercy Medical Center, IncBaltimore, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Dayton Gastroenterology- EnglewoodBeavercreek, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Northwest Gastroenterology AssociatesBellevue, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Beth Israel Deaconess Medical CenterBoston, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Massachusetts General HospitalBoston, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Arizona Liver HealthChandler, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • The University of North Carolina at Chapel HillChapel Hill, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Medical University of South Carolina (MUSC)Charleston, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Carolinas Medical Center -Center for Liver Disease and Transplant-Kidney Transplant CentreCharlotte, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • University of Virginia Medical CenterCharlottesville, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Northwestern MedicineChicago, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Rush University Medical CenterChicago, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • The University of Chicago MedicineChicago, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Cleveland Clinic FoundationCleveland, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • University Hospitals Cleveland Medical Center*Cleveland, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Peak Gastroenterology AssociatesColorado Springs, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Gastro OneCordova, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Southern California Research CenterCoronado, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Methodist Health Systems Clinical Research InstituteDallas, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • University of Texas Southwestern Medical CenterDallas, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Henry Ford Health SystemDetroit, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Duke University Health SystemDurham, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • South Denver Gastroenterology, P.C.Englewood, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Penn State Milton S.Hershey Medical Center - Penn State Hershey Cancer InstituteHershey, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Baylor College of Medicine - Advanced Liver TherapiesHouston, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Houston Methodist HospitalHouston, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Liver Associates of Texas, P.A.Houston, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Indiana University School of MedicineIndianapolis, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • The University of Iowa Hospitals & ClinicsIowa City, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Gastrointestinal Associates of Northeast TennesseeJohnson City, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • University of California San DiegoLa Jolla, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Rocky Mountain Gastroenterology (RMG)Littleton, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Keck Medicine Of USC - USC Healthcare Center 1Los Angeles, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • University of Louisville School of MedicineLouisville, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • University of Wisconsin Hospitals and ClinicsMadison, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • University of Miami - Schiff Center for Liver DiseasesMiami, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Intermountain Medical CenterMurray, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Gastroenterology Health Partners, PLLC (Southern Indiana Location)New Albany, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Yale Medical Group - Yale Digestive Diseases -Temple Medical Center LocationNew Haven, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Mount SInai Medical CenterNew York, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • NYU Langone Gastroenterology and Hepatology AssociatesNew York, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Weill Medical College of Cornell UniversityNew York, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Deaconess GI Specialty CenterNewburgh, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • University of Nebraska Medical CenterOmaha, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • California Liver Research InstitutePasadena, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Thomas Jefferson University Hospital - Jefferson Digestive Disease Institute (JDDI)Philadelphia, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • University of Pennsylvania - Perelman Center for Advanced MedicinePhiladelphia, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Mayo Clinic in ArizonaPhoenix, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • University GastroenterologyProvidence, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Rapid City Medical CenterRapid City, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Stanford UniversityRedwood City, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Bon Secours Richmond Community Hospital LLC d/b/a Bon Secours Liver Institute of RichmondRichmond, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Virginia Commonwealth University Medical CenterRichmond, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • Mayo Clinic Cancer Center (MCCC) - RochesterRochester, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • University of Rochester Medical CenterRochester, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • University of California, Davis Medical CenterSacramento, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • American Research Corporation at the Texas Liver InstituteSan Antonio, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Starhope Liver Center, PA - Starhope Clinical Research, LLCSan Antonio, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Sutter Health Van Ness Campus Medical Office BuildingSan Francisco, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • University of California San Francisco Medical CenterSan Francisco, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Velocity Clinical Research, SeattleSeattle, United StatesContact: Ipsen Clinical Study EnquiriesTaking people
  • Saint Louis UniversitySt Louis, United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting
  • MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH)Washington D.C., United StatesContact: Ipsen Clinical Study EnquiriesNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to find out how well and safely elafibranor works compared to placebo in adult participants with Primary sclerosing cholangitis (PSC). PSC is a rare disease that causes inflammation and scarring of the bile ducts in the liver. Over time, this can lead to liver damage and serious health problems, including the need for a liver transplant and death.

Read full original descriptionShow less

In this study, about 350 participants with large duct PSC will take part. Participants will be randomized to receive either elafibranor 120 mg once daily or a placebo (a tablet with no active medicine). The study includes a screening period, an treatment period, and a post-treatment safety follow-up.

During the study, participants will undergo routine clinical assessments, laboratory testing, imaging evaluations, and complete patient-reassessments to evaluate liver disease progression, symptoms, quality of life and safety.

Following the end of treatment, participants will complete a safety follow-up period at approximately four weeks. Participants may withdraw from the study at any time. Each participant may be in the study for several years, as the treatment period will continue until the study reaches enough health events among participants, which is expected to take about 5 years.

The 2 groups in the trial

  • Elafibranor 120 mgTreatment being tested

    Participants will take 1 tablet of elafibranor 120 mg orally once daily

    Treatment: Elafibranor

  • PlaceboPlacebo, for comparison

    Participants will take 1 placebo tablet orally once daily

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis
Fit questions
Built from NCT07387549, who can take part
Record updated
23 October 2026